CMAB008 not checked

Taizhou Mabtech Pharmaceutical Co.,Ltd

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 4 trial completes
Trials
28 active
31 in total · 30 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Crohn Disease
Main trialPhase 4
“Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.”In the company’s words, NCT05906576 on ClinicalTrials.gov
Other names
Infliximab

Other drugs for Crohn Disease

All 45 drugs for Crohn Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials31

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Nov 2026 Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Phase 4Authorised not given Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis
Phase 2Authorised not given Infliximab for non-Crohn Anal Fistulas
Phase 3Authorised not given Efficacy and safety of infliximab for immune checkpoint inhibitor induced colitis: a multinational, randomised, open label, phase III trial - The iCaD Study
Phase 4Authorised not given Model-informed precision dosing during infliximab rescue therapy for patients with steroid-refractory acute severe ulcerative colitis: an exploratory study
Phase 2Authorised not given Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial.
Phase 2Authorised not given Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING).
Phase 2Authorised not given Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis (RESPECT).
Phase 4Authorised not given Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patients (Pro-RAPID)
Phase 4Authorised not given Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
Phase 4Authorised not given Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL trial
Phase 3Authorised not given A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
Phase 3Ended not given Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients with Active Crohn’s Disease or Ulcerative Colitis
Phase 4Ended not given PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Phase 2Authorised not given INTOReTAK - Multicentre, randomized, prospective trial evaluating the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis - INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis
Phase 4Authorised not given Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis
Phase 4Authorised not given Stopping anti-TNF treatment in Crohn's and Colitis patients in remission
Phase 3Authorised not given FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
Phase 4Authorised not given FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring
Phase 3/4Authorised not given RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial)
Phase 3Authorised not given TAWIS - Evaluation of TNF-alpha antagonists (Infliximab) withdrawal in sarcoidosis : a prospective, randomized, controlled trial.
Phase 4Ended not given A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn’s Disease ( Direct-CD)
Phase 3/4Authorised not given IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Phase 4Authorised not given Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial
Phase 4Authorised not given Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)
Phase 2Authorised not given Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial
Phase 4Authorised not given Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial
Phase 4Authorised not given Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Phase 4Authorised not given DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial
Phase 4Authorised not given Subcutaneous Infliximab for perianal fistulizing Crohn’s disease
Phase 3Authorised not given A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CMAB008

Following is part of Solo: you see every change to CMAB008 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in